Heron Therapeutics Inc HRTX announced on Monday that the U.S. Food and Drug Administration (FDA) has not taken any action on its New Drug Application (NDA) for SUSTOL.
The FDA informed Heron Therapeutics that it has not yet concluded a review of the NDA despite a January 17, 2016, deadline expected late February.
Shares of Heron Therapeutics were trading lower by more than 4 percent shortly after Monday's market open, and have since continued to drop.
Heron Therapeutics added that the FDA could not yet provide an anticipated action date but will communicate a new action date later on this week.
At the time of this publication, heron was trading down 11.53 percent on the day at $16.57.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.